Ranchi News Desk

Alzheimer’s Disease Pipeline Insight | Companies – Biogen, AZTherapies, Cerecin, Neurotrope, Synaptogenix, INmune Bio, Cassava Sciences, EIP Pharma, Neuraly, AB Science, Cortexyme, and others

 Breaking News
  • No posts were found

Alzheimer’s Disease Pipeline Insight | Companies – Biogen, AZTherapies, Cerecin, Neurotrope, Synaptogenix, INmune Bio, Cassava Sciences, EIP Pharma, Neuraly, AB Science, Cortexyme, and others

May 24
15:52 2023
Alzheimer’s Disease Pipeline Insight | Companies - Biogen, AZTherapies, Cerecin, Neurotrope, Synaptogenix, INmune Bio, Cassava Sciences, EIP Pharma, Neuraly, AB Science, Cortexyme, and others

DelveInsight’s, “Alzheimer’s Disease Pipeline Insights 2023” report provides comprehensive insights about 150+ companies and 160+ pipeline drugs in Alzheimer’s Disease pipeline landscape. It covers the Alzheimer’s Disease pipeline drug profiles, including Alzheimer’s Disease clinical trials and nonclinical stage products. It also covers the Alzheimer’s Disease therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

To explore more information on the latest breakthroughs in the Alzheimer’s Disease Pipeline treatment landscape of the report, click here @ Alzheimer’s Disease Pipeline Outlook

 

Key Takeaways from the Alzheimer’s Disease Pipeline Report

  • DelveInsight’s Alzheimer’s Disease Pipeline report depicts a robust space with 150+ active players working to develop 160+ pipeline therapies for Alzheimer’s Disease.
  • The leading Alzheimer’s Disease Companies include Biogen, AZTherapies, Cerecin, Neurotrope, Synaptogenix, INmune Bio, Cassava Sciences, EIP Pharma, Neuraly, AB Science, Cortexyme, Anavex Life Sciences, Athira Pharma, Time Therapeutics, Denali Therapeutics Inc., Alector Inc., Lexeo Therapeutics, TrueBinding, Inc., Vaccinex Inc., Annovis Bio Inc., Eisai Inc., Hoffmann-La Roche, Ionis Pharmaceuticals, Otsuka Pharmaceutical, Cognition Therapeutics, Merck Sharp & Dohme LLC, ImmunoBrain Checkpoint, AbbVie, AriBio Co., Ltd., Oryzon Genomics S.A., Eli Lilly and Company, Neurokine Therapeutics, Excelsior, Seelos Therapeutics Inc., Janssen Research & Development, Shanghai Hengrui Pharmaceutical, reMYND, Alzinova AB, VTBIO Co. LTD, BioVie Inc., Prothena Corporation, Coya Therapeutics Inc., and others
  • Promising Alzheimer’s Disease Pipeline Therapies include ALZT-OP1, Tricaprilin, Bryostatin-1, INB03, Sumifilam, Neflamapimod, Pegylated exenatide, NLY-02, Masitinib, Atuzaginstat, COR588, Blarcamesine, NDX-1017, Bromocriptine, DNL788, AL002, CMS121,  LX1001,  TB006, Pepinemab, Posiphen, E2814, RO7126209, IONIS MAPTRx,   Brexpiprazole, CT1812, MK-1942, IBC Ab002, ABBV-916,  AR1001, ORY-2001, LY3372689, MW150,  EX039, SLS-005,  Seltorexant, Donanemab,  SHR-1707, REM0046127,  ALZ-101, VT301, NE3107, PRX005, MK-6240,  and others.
  • Alzheimer’s Disease Companies and academics are working to assess challenges and seek opportunities that could influence Pheochromocytoma R&D. The Alzheimer’s Disease pipeline therapies under development are focused on novel approaches to treat/improve Alzheimer’s Disease.

 

For further information, refer to the detailed Alzheimer’s Disease Unmet Needs, Alzheimer’s Disease Market Drivers, and Alzheimer’s Disease Market Barriers, click here for Alzheimer’s Disease Ongoing Clinical Trial Analysis

 

Alzheimer’s Disease Overview

 Alzheimer’s disease is a brain disorder that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks. In most people with the disease — those with the late-onset type symptoms first appear in their mid-60s. Early-onset Alzheimer’s occurs between a person’s 30s and mid-60s and is very rare. Alzheimer’s disease is the most common cause of dementia among older adults.

 

Request a sample and discover the recent advances in Alzheimer’s Disease Ongoing Clinical Trial Analysis and Medications, click here @ Alzheimer’s Disease Treatment Landscape

 

Alzheimer’s Disease Emerging Drugs Profile

  • Donanemab: Eli Lilly and Company

Donanemab is a humanized IgG1 antibody directed at an N-terminal pyroglutamate Aβ epitope that is present only in established plaques. It is specific for this epitope and shows no off-target binding to other Aβ species, neurotransmitters, or their receptors and has no known symptomatic effect. In a phase 1a study involving patients with amyloid-positive prodromal-to-moderate Alzheimer’s disease, the safety, pharmacokinetics, and pharmacodynamics of donanemab were assessed after the administration of multiple doses.

  • Masitinib: AB Science

Masitinib (AB1010) is an oral tyrosine kinase inhibitor that has demonstrated neuroprotective action in neurodegenerative diseases via inhibition of mast cell and microglia/macrophage activity, possibly by switching the neuroimmune system from a neurotoxic state towards a neuroprotective state through remodeling of the neuronal microenvironment.The rationale to use masitinib in Alzheimer’s disease patients is supported by preclinical evidence demonstrating that the pharmacological action of masitinib in mast cells can restore normal spatial learning performance in a mouse model of Alzheimer’s disease and promotes recovery of synaptic markers. Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of Alzheimer Disease.

  • XPro1595 (Pegipanermin): INmune Bio, Inc.

XPro1595 is a next-generation inhibitor of tumor necrosis factor (TNF) that uses a dominant-negativeTNF technology that is very different from approved TNF inhibitors that block the effects of both soluble and trans-membrane TNF. Pegipanermin neutralizes soluble TNF, without affecting trans-membrane TNF or TNF receptors. XPro1595 could have substantial beneficial effects in patients with Alzheimer’s and other neurodegenerative diseases by decreasing neuroinflammation. Currently the drug is in Phase II stage of Clinical trial evaluation for the treatment of Alzheimer’s disease.

 

Dive deep into rich insights for drugs for Alzheimer’s Disease Market Drivers and Alzheimer’s Disease Market Barriers, click here @ Alzheimer’s Disease Unmet Needs and Analyst Views

 

Alzheimer’s Disease Pipeline Therapeutics Assessment

There are approx. 150+ key companies which are developing the therapies for Alzheimer’s disease. The companies which have their Alzheimer’s disease drug candidates in the most advanced stage, i.e. Preregistration include, Eli Lilly and Company.

 

Scope of the Alzheimer’s Disease Pipeline Report

  • Coverage- Global
  • Alzheimer’s Disease Companies- Biogen, AZTherapies, Cerecin, Neurotrope, Synaptogenix, INmune Bio, Cassava Sciences, EIP Pharma, Neuraly, AB Science, Cortexyme, Anavex Life Sciences, Athira Pharma, Time Therapeutics, Denali Therapeutics Inc., Alector Inc., Lexeo Therapeutics, TrueBinding, Inc., Vaccinex Inc., Annovis Bio Inc., Eisai Inc., Hoffmann-La Roche, Ionis Pharmaceuticals, Otsuka Pharmaceutical, Cognition Therapeutics, Merck Sharp & Dohme LLC, ImmunoBrain Checkpoint, AbbVie, AriBio Co., Ltd., Oryzon Genomics S.A., Eli Lilly and Company, Neurokine Therapeutics, Excelsior, Seelos Therapeutics Inc., Janssen Research & Development, Shanghai Hengrui Pharmaceutical, reMYND, Alzinova AB, VTBIO Co. LTD, BioVie Inc., Prothena Corporation, Coya Therapeutics Inc., and others
  • Alzheimer’s Disease Pipeline Therapies- ALZT-OP1, Tricaprilin, Bryostatin-1, INB03, Sumifilam, Neflamapimod, Pegylated exenatide, NLY-02, Masitinib, Atuzaginstat, COR588, Blarcamesine, NDX-1017, Bromocriptine, DNL788, AL002, CMS121,  LX1001,  TB006, Pepinemab, Posiphen, E2814, RO7126209, IONIS MAPTRx,   Brexpiprazole, CT1812, MK-1942, IBC Ab002, ABBV-916,  AR1001, ORY-2001, LY3372689, MW150,  EX039, SLS-005,  Seltorexant, Donanemab,  SHR-1707, REM0046127,  ALZ-101, VT301, NE3107, PRX005, MK-6240,  and others.
  • Alzheimer’s Disease Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Alzheimer’s Disease Mergers and acquisitions, Alzheimer’s Disease Licensing Activities @ Alzheimer’s Disease Emerging Drugs, and Recent Trends

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Alzheimer’s Disease: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Alzheimer’s Disease– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Preregistration)
  8. Donanemab: Eli Lilly and Company
  9. Late Stage Products (Phase III)
  10. Masitinib: AB Science
  11. Drug profiles in the detailed report…..
  12. Mid Stage Products (Phase II)
  13. XPro1595 (Pegipanermin): INmune Bio, Inc.
  14. Drug profiles in the detailed report…..
  15. Early Stage Products (Phase I)
  16. Drug Name: Company Name
  17. Drug profiles in the detailed report…..
  18. Preclinical and Discovery Stage Products
  19. Drug Name: Company Name
  20. Drug profiles in the detailed report…..
  21. Inactive Products
  22. Alzheimer’s Disease Key Companies
  23. Alzheimer’s Disease Key Products
  24. Alzheimer’s Disease- Unmet Needs
  25. Alzheimer’s Disease- Market Drivers and Barriers
  26. Alzheimer’s Disease- Future Perspectives and Conclusion
  27. Alzheimer’s Disease Analyst Views
  28. Alzheimer’s Disease Key Companies
  29. Appendix

 

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services